4-[6-(5-pyridin-4-yl-1H-indazol-3-yl)pyrimidin-4-yl]morpholine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-[6-(5-pyridin-4-yl-1H-indazol-3-yl)pyrimidin-4-yl]morpholine
• 化学式: C₂₀H₁₈N₆O
• 分子量: 358.403
• InChiKey: YHTCVPYUCVCMIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  79.8
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY<br/>[FR] COMPOSÉS INHIBANT L'ACTIVITÉ ENZYMATIQUE DE LA KINASE À SÉQUENCE RÉPÉTÉE RICHE EN LEUCINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014137719A1

  公开（公告）日：2014-09-12

  The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

  本发明涉及一种对LRRK2激酶具有很强抑制作用的吲唑啉化合物，可用于治疗或预防LRRK2激酶参与的疾病，如帕金森病。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗LRRK2激酶参与的疾病中使用这些化合物和组合物。
• COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY
  申请人：MILLER Michael

  公开号：US20160009696A1

  公开（公告）日：2016-01-14

  The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

  本发明涉及一种indazole化合物，它是LRRK2激酶的有效抑制剂，可用于治疗或预防LRRK2激酶参与的疾病，例如帕金森病。本发明还涉及包含这些化合物的药物组合物以及使用这些化合物和组合物在预防或治疗LRRK-2激酶参与的这些疾病中的应用。
• US9416126B2
  申请人：——

  公开号：US9416126B2

  公开（公告）日：2016-08-16